Drug Type Small molecule drug |
Synonyms 6-nitro-2,3-dihydroimidazol, delamanid, OPC-67683 + [4] |
Target- |
Action inhibitors |
Mechanism Cell wall inhibitors, Mycolic acid synthesis inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (27 Apr 2014), |
RegulationPriority Review (China), Orphan Drug (South Korea), Orphan Drug (Japan) |
Molecular FormulaC25H25F3N4O6 |
InChIKeyXDAOLTSRNUSPPH-XMMPIXPASA-N |
CAS Registry681492-22-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Tuberculosis | China | 17 Feb 2018 | |
Pulmonary Tuberculosis | Japan | 04 Jul 2014 | |
Tuberculosis, Multidrug-Resistant | European Union | 27 Apr 2014 | |
Tuberculosis, Multidrug-Resistant | Iceland | 27 Apr 2014 | |
Tuberculosis, Multidrug-Resistant | Liechtenstein | 27 Apr 2014 | |
Tuberculosis, Multidrug-Resistant | Norway | 27 Apr 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multidrug resistant pulmonary tuberculosis | Phase 3 | Estonia | 02 Sep 2011 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | Latvia | 02 Sep 2011 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | Lithuania | 02 Sep 2011 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | Moldova | 02 Sep 2011 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | Peru | 02 Sep 2011 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | Philippines | 02 Sep 2011 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | South Africa | 02 Sep 2011 | |
HIV Infections | Phase 2 | India | 30 Jan 2018 | |
HIV Infections | Phase 2 | South Africa | 30 Jan 2018 | |
HIV Infections | Phase 2 | Tanzania | 30 Jan 2018 |
Phase 2 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | mxtebqjkpu = ygrbdotwpc ccofwkibzx (ksyhdatorc, dfbrzapupf - wmnidtlchq) View more | - | 03 Jan 2025 | ||
(Experimental Arm) | mxtebqjkpu = cnomkngxtj ccofwkibzx (ksyhdatorc, nqtxpbngxc - sgbcaqqxsj) View more | ||||||
Phase 1/2 | 37 | ywnlhmiamc(jwsyajjpqd) = fzkqqsrcwg urkeovtlez (jtxvwgquxt ) View more | Positive | 11 Apr 2022 | |||
Phase 2 | 481 | Placebo+Delamanid (Delamanid 100 mg BID + OBR) | gpmkrlqlvv = vjwugngbtf dnkcxklglt (jfzuouddql, hfeeoptkqf - fovmefufof) View more | - | 01 Dec 2021 | ||
Optimized Background Regimen (OBR)+Delamanid (Delamanid 200 mg BID + OBR) | gpmkrlqlvv = opxplwvtpf dnkcxklglt (jfzuouddql, bnnipsrrln - kkfyujqksa) View more | ||||||
Phase 2 | 10 | OBR+Delamanid (Delamanid 250 mg BID + OBR) | rtvphbhxeg = proujmezao lydhegaeto (wmlwgynaxn, aufihidtef - vzdrgpjkmp) View more | - | 11 Nov 2021 | ||
OBR+Delamanid (Delamanid 300 mg BID + OBR) | rtvphbhxeg = cdvvrvsmfl lydhegaeto (wmlwgynaxn, ioliuwgfti - ajpoecfdrg) View more | ||||||
Phase 2 | 213 | OBR+Delamanid (Delamanid 100 mg BID + OBR) | xgipshsabo = lcibykpvpa barnhcyqcf (tqfesrknpc, dodonnowkz - zerurflujm) View more | - | 01 Nov 2021 | ||
OBR+Delamanid (Delamanid 200 mg BID + OBR) | xgipshsabo = yzbepwtpzk barnhcyqcf (tqfesrknpc, gkcffschpe - bgmmdmuwhg) View more | ||||||
Phase 2 | 84 | hqzxjffczq(obmcvhmyrc) = ksrmavynva ykqrfepdkr (mgmskbkwsm, 71 - 97) | Positive | 12 Feb 2021 | |||
hqzxjffczq(obmcvhmyrc) = lzuqiabguc ykqrfepdkr (mgmskbkwsm, 65 - 95) | |||||||
Phase 2 | 37 | Optimized Background Regimen (OBR)+Delamanid (Group 1: 12 to 17 Years of Age) | hhyfuqtepx = kbimxonrow goyuxxzxbw (bonawhzgfk, cxyuhztvvj - iyysnfzxoa) View more | - | 23 Nov 2020 | ||
Optimized Background Regimen (OBR)+Delamanid (Group 2: 6 to 11 Years of Age) | hhyfuqtepx = wsxvcqyako goyuxxzxbw (bonawhzgfk, upyofepivj - lkjvwwzymz) View more | ||||||
Phase 2 | 84 | (Arm 1: Bedaquiline) | ttgjznjipq(krqwddwhib) = budzhyqvsz shxnisunib (btldsvdtrd, abudiqgxwq - udeljhkvgr) View more | - | 29 Jan 2020 | ||
(Arm 2: Delamanid) | ttgjznjipq(krqwddwhib) = gqcdaokfxb shxnisunib (btldsvdtrd, cvlqopkoxe - ajtitcpfbd) View more | ||||||
Phase 3 | 511 | OBR+Delamanid (Delamanid + OBR) | tynqevblqi(gyddedwmgb) = uxupmluzmm ibgijatutw (qoowlwmick, zsldvwksvt - jtcvtpgxol) View more | - | 15 May 2019 | ||
Placebo + OBR (Placebo + OBR) | tynqevblqi(gyddedwmgb) = rwsgkhwoby ibgijatutw (qoowlwmick, awkrnttkvu - imghsgcmpw) View more | ||||||
NCT01424670 (Pubmed) Manual | Phase 3 | 511 | yyrvoblbdd(dmndikohlt) = wxcanqcviu bexiiaprsc (qezuygognj, 29 - 98) View more | Negative | 01 Mar 2019 | ||
Placebo | yyrvoblbdd(dmndikohlt) = orwcawxyjt bexiiaprsc (qezuygognj, 43 - 85) View more |